

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

NCT06647134

Status RECRUITING
Sponsor M.D. Anderson Cancer Center
Enrollment 20 participants

Key Eligibility Criteria

Inclusion (4)

- The criteria are:
- Patients aged 18 years and above
- English (conversational level) speaking, with the ability to give informed consent
- Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy

Exclusion (2)

- Acutely life-threatening or worsening cancer
- Hearing impairment functionally limiting participation in verbal interview

Locations (1 total)

MD Anderson Cancer Center, Houston, Texas, United States